Quel est l’impact du cannabidiol sur la psychose ? (notice n° 1350245)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03272cam a2200313 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20250504013043.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Platteau, Jeroen |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Quel est l’impact du cannabidiol sur la psychose ? |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2025.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 71 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Cannabidiol (CBD) is a cannabinoid derived from the Cannabis sativa plant. CBD has already been shown to be effective in treating multiple sclerosis and certain forms of epilepsy. Recently, studies have also explored the effects of CBD on psychiatric disorders. Some studies show a positive effect on the treatment of psychosis, while others show no effect. There are also some promising results in the treatment of social anxiety, although fewer studies have been conducted on this topic. For other psychiatric illnesses, there is no evidence yet that CBD can have a positive impact. Since existing studies have been conducted with few participants, larger-scale studies will be needed to demonstrate its efficacy and safety. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | El cannabidiol (CBD) es un cannabinoide proveniente de la planta Cannabis sativa. El CBD ya ha demostrado su eficacia en el tratamiento de ciertas formas de epilepsia y esclerosis múltiple. Estudios recientes también han explorado los efectos del CBD en trastornos psiquiátricos. Algunos estudios muestran un efecto positivo en los trastornos psicóticos, mientras que otros no muestran ningún efecto. También hay algunos resultados prometedores para el tratamiento de la ansiedad social, aunque hay menos estudios sobre este tema. Para otras enfermedades psiquiátricas, todavía no hay pruebas de que el CBD pueda tener un impacto positivo. Dado que los estudios existentes se han realizado con pocos participantes, serán necesarios estudios a mayor escala para demostrar su eficacia y seguridad. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Le cannabidiol (CBD) est un cannabinoïde provenant de la plante Cannabis sativa. Le CBD a déjà montré son efficacité pour le traitement de certaines formes d’épilepsie et de la sclérose en plaques. Récemment, des études ont également exploré les effets du CBD sur les troubles psychiatriques. Quelques études démontrent un effet positif sur les troubles psychotiques, tandis que d’autres ne montrent pas d’effet. Il existe également quelques résultats prometteurs dans le traitement de l’anxiété sociale, bien qu’il y ait moins d’études à ce sujet. Pour d’autres maladies psychiatriques il n’existe pas encore de preuve que le CBD peut avoir un impact positif. Comme les études existantes ont été effectuées avec peu de participants, des études à plus large échelle seront nécessaires pour montrer son efficacité et sa sécurité. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anxiété |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cannabidiol |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cannabis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | psychose |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | thérapeutique médicamenteuse |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | anxiety |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cannabidiol |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cannabis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | drug therapy |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | psychosis |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Dal, Sylvain |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | L'information psychiatrique | 101 | 4 | 2025-04-28 | p. 227-231 | 0020-0204 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://shs.cairn.info/revue-l-information-psychiatrique-2025-3-page-227?lang=fr&redirect-ssocas=7080">https://shs.cairn.info/revue-l-information-psychiatrique-2025-3-page-227?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux